Merck KGaA (MKKGY)

OTCMKTS · Delayed Price · Currency is USD
27.24
-0.15 (-0.55%)
Apr 24, 2025, 9:44 AM EDT
-13.22%
Market Cap 59.60B
Revenue (ttm) 21.90B
Net Income (ttm) 2.88B
Shares Out n/a
EPS (ttm) 6.61
PE Ratio 20.73
Forward PE n/a
Dividend 0.32 (1.17%)
Ex-Dividend Date Apr 29, 2025
Volume 100
Average Volume 163,589
Open 27.09
Previous Close 27.39
Day's Range 27.09 - 27.24
52-Week Range 24.32 - 39.17
Beta 0.70
RSI 51.99
Earnings Date May 15, 2025

About Merck KGaA

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing a... [Read more]

Sector Healthcare
Founded 1668
Employees 59,020
Stock Exchange OTCMKTS
Ticker Symbol MKKGY
Full Company Profile

Financial Performance

In 2024, Merck KGaA's revenue was 21.16 billion, an increase of 0.78% compared to the previous year's 20.99 billion. Earnings were 2.78 billion, a decrease of -1.66%.

Financial numbers in EUR Financial Statements

News

Merck KGaA: Still A Bit Too Expensive

Merck KGaA's stock remains a 'hold' due to its high valuation, trading at an earnings multiple of around 20 and a 4.5% free cash flow yield. Read why MKGAF is a hold.

5 weeks ago - Seeking Alpha

Resilience is part of our DNA, says Merck KGaA CEO

Belén Garijo, CEO of Merck KGaA, said the German pharmaceutical company has increased its readiness to deal with the ongoing geopolitical uncertainty, and is confident it will continue delivering prof...

6 weeks ago - CNBC International TV

Merck KGaA (MKGAF) Q4 2024 Earnings Call Transcript

Merck KGaA (OTCPK:MKGAF) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Florian Schraeder - Head of Investor Relations Belen Garijo - Group CEO Helene von Roeder - Group...

6 weeks ago - Seeking Alpha

Merck KGaA sees forex-adjusted earnings growth of up to 8% this year

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor chemicals and for lab equipment in biotech drug production.

7 weeks ago - Reuters

Merck KGaA to replace two executives with company veterans

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new leadership from June but it added that its strategy remains unchanged.

2 months ago - Reuters

Exclusive: Germany's Merck KGaA in talks to buy US cancer biotech firm Springworks, sources say

Merck KGaA , the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics , according to people familiar with the matter...

2 months ago - Reuters

Merck KGaA says high asset prices call for prudent M&A approach

The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.

3 months ago - Reuters

Mirror Biologics Enters Clinical Collaboration with Merck KGaA, Darmstadt, Germany in Metastatic Colorectal Cancer

TAMPA, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mirror Biologics, Inc., specializing in development and manufacturing of immunotherapy products where the active ingredient is living, non-genetically al...

3 months ago - GlobeNewsWire

Merck KGaA (MKGAF) Q3 2024 Earnings Call Transcript

Merck KGaA (OTCPK:MKGAF) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Lopez - Chair of Executive Board & CEO He...

5 months ago - Seeking Alpha

Merck KGaA Q3 earnings rise faster than expected on lower costs

Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by cost-cutting measures and temporarily lower spending on drug research and development.

5 months ago - Reuters

Merck KGaA: A Continued Long-Term Upside Despite Some Lag

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 was mixed-positive. Going into Q3 2024, I consider MKGAF to be an attracti...

6 months ago - Seeking Alpha

AI is driving semiconductor industry, says CEO Electronics at Merck KgaA

Kai Beckmann, a member of the executive board and the CEO Electronics at Merck KgaA, discusses the use of AI in the semiconductor industry.

6 months ago - CNBC International TV

Merck KGaA Shares Jump on Expectations of AI Boost

The German company said booming artificial-intelligence demand would help its electronics sales grow faster than previously expected over the medium term.

6 months ago - WSJ

Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the first patient has been dosed in the Phase III MyClad trial (NCT064635...

8 months ago - Business Wire

Merck KGaA (MKGAF) Q2 2024 Earnings Call Transcript

Merck KGaA (OTCPK:MKGAF) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Lopez - Chair of Executive Board & CEO Helene...

9 months ago - Seeking Alpha

Merck KGaA: The Drop Makes The Upside All The Sweeter

Merck KGaA remains undervalued with strong fundamentals and diverse business portfolio in healthcare, life sciences, and electronics. The company has above-average margins compared to the broader mark...

10 months ago - Seeking Alpha

Merck KGaA, Darmstadt, Germany, Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating ...

10 months ago - Business Wire

Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced new research from the company's diverse oncology portfolio will be presented at the 2024 American ...

11 months ago - Business Wire

Merck KGaA (MKGAF) Q1 2024 Earnings Call Transcript

Merck KGaA (OTCPK:MKGAF) Q1 2024 Results Conference Call May 15, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO Ma...

1 year ago - Seeking Alpha

Merck KGaA's Q1 adjusted profit declines less than feared

Merck KGaA on Wednesday reported better-than-expected adjusted earnings, helped by strong demand for its pharmaceuticals and amid currency-adjusted sales growth in semiconductor materials.

1 year ago - Reuters

We are expecting life sciences to be stronger in the second half of 2024, says Merck KGaA CEO

Belén Garijo, CEO of Merck KGaA, discusses full-year results and her outlook for the life sciences industry.

1 year ago - CNBC International TV

Merck KGaA (MKGAF) Q4 2023 Earnings Call Transcript

Merck KGaA (OTCPK:MKGAF) Q4 2023 Results Conference Call March 7, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO M...

1 year ago - Seeking Alpha

Merck KGaA forecasts return to organic earnings growth in 2024

Merck KGaA predicted a return to modest operating earnings growth, when adjusted for currency headwinds, citing a gradual recovery in demand for specialty materials that are used to make biotech drugs...

1 year ago - Reuters

'Europe is lagging behind' on innovation: Merck KGaA CEO

Belén Garijo, CEO of science and technology company Merck KGaA, discusses European regulation, growth and innovation with CNBC at Davos.

1 year ago - CNBC International TV

4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn't One.

Drug stocks GSK, Sanofi, Merck KGaA, and Novartis look set for a good year on strong cash flows and attractive valuations, says UBS.

1 year ago - Barrons